These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 38771737)
1. KAT8 enhances the resistance of lung cancer cells to cisplatin by acetylation of PKM2. Li Z; Lu X; Zhang J; Liu T; Xu M; Liu S; Liang J Anticancer Drugs; 2024 Sep; 35(8):732-740. PubMed ID: 38771737 [TBL] [Abstract][Full Text] [Related]
2. Apoptin Inhibits Glycolysis and Regulates Autophagy by Targeting Pyruvate Kinase M2 (PKM2) in Lung Cancer A549 Cells. Song G; Shang C; Zhu Y; Xiu Z; Li Y; Yang X; Ge C; Han J; Jin N; Li Y; Li X; Fang J Curr Cancer Drug Targets; 2024; 24(4):411-424. PubMed ID: 36284386 [TBL] [Abstract][Full Text] [Related]
3. Hypoxia-induced lncRNA-AC020978 promotes proliferation and glycolytic metabolism of non-small cell lung cancer by regulating PKM2/HIF-1α axis. Hua Q; Mi B; Xu F; Wen J; Zhao L; Liu J; Huang G Theranostics; 2020; 10(11):4762-4778. PubMed ID: 32308748 [No Abstract] [Full Text] [Related]
4. Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2. Wang D; Zhao C; Xu F; Zhang A; Jin M; Zhang K; Liu L; Hua Q; Zhao J; Liu J; Yang H; Huang G Theranostics; 2021; 11(6):2860-2875. PubMed ID: 33456577 [TBL] [Abstract][Full Text] [Related]
5. CircPTK2 inhibits cell cisplatin (CDDP) resistance by targeting miR-942/TRIM16 axis in non-small cell lung cancer (NSCLC). Wang Y; Wu Y; Xie S Bioengineered; 2022 Feb; 13(2):3651-3664. PubMed ID: 35230201 [TBL] [Abstract][Full Text] [Related]
6. Isovitexin potentiated the antitumor activity of cisplatin by inhibiting the glucose metabolism of lung cancer cells and reduced cisplatin-induced immunotoxicity in mice. Chen RL; Wang Z; Huang P; Sun CH; Yu WY; Zhang HH; Yu CH; He JQ Int Immunopharmacol; 2021 May; 94():107357. PubMed ID: 33715980 [TBL] [Abstract][Full Text] [Related]
7. Thyroid hormone enhances efficacy of cisplatin in lung cancer patients via down-regulating GLUT1 expression and reversing the Warburg effect. Fan C; Ren Y; Zhang W; Wen J; Zhang W; Lin S; Bai Y; Zheng T; Abay B; Li M; Fan L Mitochondrion; 2024 Sep; 78():101919. PubMed ID: 38876298 [TBL] [Abstract][Full Text] [Related]
8. TFAP2A Upregulates SKA3 to Promote Glycolysis and Reduce the Sensitivity of Lung Adenocarcinoma Cells to Cisplatin. Liu G; Liu X; Zeng W; Zhou W Pharmacology; 2024; 109(4):202-215. PubMed ID: 38643755 [TBL] [Abstract][Full Text] [Related]
9. Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer. Wang X; Zhang H; Yang H; Bai M; Ning T; Deng T; Liu R; Fan Q; Zhu K; Li J; Zhan Y; Ying G; Ba Y Mol Oncol; 2020 Mar; 14(3):539-555. PubMed ID: 31901148 [TBL] [Abstract][Full Text] [Related]
10. KAT2A Promotes the Succinylation of PKM2 to Inhibit its Activity and Accelerate Glycolysis of Gastric Cancer. Zhang C; Huang Z Mol Biotechnol; 2024 Jun; 66(6):1446-1457. PubMed ID: 37294531 [TBL] [Abstract][Full Text] [Related]
11. The transcription factor TEAD4 enhances lung adenocarcinoma progression through enhancing PKM2 mediated glycolysis. Hu Y; Mu H; Deng Z Cell Biol Int; 2021 Oct; 45(10):2063-2073. PubMed ID: 34196069 [TBL] [Abstract][Full Text] [Related]
12. Pyruvate Kinase M2 Modulates Esophageal Squamous Cell Carcinoma Chemotherapy Response by Regulating the Pentose Phosphate Pathway. Fukuda S; Miyata H; Miyazaki Y; Makino T; Takahashi T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1461-8. PubMed ID: 25808097 [TBL] [Abstract][Full Text] [Related]
13. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling. Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094 [TBL] [Abstract][Full Text] [Related]
14. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p. Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146 [TBL] [Abstract][Full Text] [Related]
15. JARID2 promotes stemness and cisplatin resistance in non-small cell lung cancer via upregulation of Notch1. Wang Q; Wu J; Wei H; Huang H; Huang Y; Fang H; Gong X; Sun J; Wu Y; Lei C; Yu J; Hu D Int J Biochem Cell Biol; 2021 Sep; 138():106040. PubMed ID: 34246759 [TBL] [Abstract][Full Text] [Related]
16. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations. Gao J; Meng Q; Zhao Y; Chen X; Cai L BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790 [TBL] [Abstract][Full Text] [Related]
17. Pterostilbene suppresses the growth of esophageal squamous cell carcinoma by inhibiting glycolysis and PKM2/STAT3/c-MYC signaling pathway. Yang Y; Li S; Shi W; Jin G; Guo D; Li A; Wang B; Lu B; Feng S Int Immunopharmacol; 2024 Dec; 142(Pt B):113247. PubMed ID: 39321706 [TBL] [Abstract][Full Text] [Related]
18. [Effect of down-regulation of survivin gene on apoptosis and cisplatin resistance in cisplatin resistant human lung adenocarcinoma A549/CDDP cells]. Zhang MC; Hu CP; Chen Q Zhonghua Zhong Liu Za Zhi; 2006 Jun; 28(6):408-12. PubMed ID: 17152483 [TBL] [Abstract][Full Text] [Related]
19. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer. Sun C; Gao W; Liu J; Cheng H; Hao J Respir Res; 2020 Aug; 21(1):210. PubMed ID: 32778129 [TBL] [Abstract][Full Text] [Related]